Liu Meihui, Tang Min, Li Ming, Gao Feng, Shi Can, Hou Jing, Zeng Wenbin
School of Pharmaceutical Sciences, Central South University 172 Tongzipo Road, Changsha, China.
Anticancer Agents Med Chem. 2016;16(12):1529-1540. doi: 10.2174/1871520616666160223113743.
As the ever more critical role of individualized therapy in the cancer treatment and management, circulating tumor cells (CTCs) have caught much attention for providing a promising way in metastases establishment, disease diagnosis and prognosis. Also, their presence has been generally considered as the rationale behind the application of systemic adjuvant chemotherapy. Therefore, CTCs open a new window for the clinical utility, especially for the diagnosis and evaluation of cancer, and move toward personalized medicine. In this review, we summarize the pros and cons of current available technologies for enrichment and detection of CTCs comprehensively. In addition, recent advances in the development of microfluidic and nanotechnology for isolation of CTCs are outlined. Furthermore, circulating tumor microemboli (CTM)-based and telomerase-based assays, the emerging methods for CTC detection and the application of CTCs in the clinic, have also been evaluated. Finally, perspectives and challenges of all these methods in the field of CTCs' isolation and detection are presented.
随着个体化治疗在癌症治疗与管理中发挥越来越关键的作用，循环肿瘤细胞（CTCs）因在转移瘤形成、疾病诊断及预后方面提供了一条有前景的途径而备受关注。此外，它们的存在通常被视为全身辅助化疗应用的理论依据。因此，循环肿瘤细胞为临床应用打开了一扇新窗口，尤其是在癌症的诊断和评估方面，并朝着个性化医疗迈进。在本综述中，我们全面总结了当前用于富集和检测循环肿瘤细胞的现有技术的优缺点。此外，还概述了用于分离循环肿瘤细胞的微流控和纳米技术发展的最新进展。此外，基于循环肿瘤微栓子（CTM）和端粒酶的检测方法、循环肿瘤细胞检测的新兴方法以及循环肿瘤细胞在临床中的应用也进行了评估。最后，阐述了所有这些方法在循环肿瘤细胞分离和检测领域面临的前景与挑战。
